Key result
Cardiac biomarkers, including high-sensitivity troponin T and B-type natriuretic peptide, act as effective predictors of subsequent cardiovascular events and subclinical myocardial injury in patients with rheumatoid arthritis.
Why the study?
Cardiovascular disease is a significant cause of death in rheumatoid arthritis, necessitating early detection methods to improve patient outcomes.
Do cardiac biomarkers (hsTropT and BNP) predict cardiovascular events in patients with rheumatoid arthritis?
Systematic Review
Do cardiac biomarkers (hsTropT and BNP) predict cardiovascular events in patients with rheumatoid arthritis?
Cardiac biomarkers such as hsTropT and BNP may be useful for early detection and prediction of cardiovascular events in patients with rheumatoid arthritis.
Supports using hsTropT and BNP for CV risk stratification in RA; extends biomarker evidence to inflammatory arthritis.
Rheumatoid arthritis (RA) is a chronic inflammatory disease that can cause permanent joint damage and premature death. Cardiovascular disease (CVD) has recently been known to have become a significant cause of death in rheumatoid arthritis patients, and cardiovascular (CV) deaths have risen by 20-50% in rheumatoid arthritis patients. Early detection methods are necessary to improve the outcome for such patients. Cardiac biomarkers have been proven to be an effective tool for evaluating the heart's activity. In this study, we have used a systematic literature review approach in order to establish an overview of the current literature, highlight the advantages of using cardiac biomarkers in early detection and diagnosis, and improve the prognosis of patients with rheumatoid arthritis. We reviewed 269 articles from January 1, 2012, to August 6, 2023, from reputed journals, out of which we focused on seven papers for in-depth analysis. This analysis considered certain factors, including the age factor, sex factor, clinical risk score, and comparison of the benefits of using this method amongst clinicians for diagnosis purposes. The systematic review has revealed that cardiac biomarkers have a good ability to act as predictors of subsequent cardiovascular events. Cardiac biomarkers include high-sensitivity troponin T (hsTropT) and B-type natriuretic peptide (BNP). We learned that the cardiac biomarkers indicate inflammation, extracellular matrix remodeling, congestion, and myocardial injury, which are linked with elementary changes in cardiac structure and function. Biomarkers could be used for the purpose of screening cardiac variations in patients with rheumatoid arthritis. However, this method tends to have its own challenges to implement, considering other factors such as age and NSAID use. Nonetheless, further research and intervention about the use of cardiac biomarkers are important in order to earn the potential to make this method available to be used worldwide to improve outcomes for patients with rheumatoid arthritis.
No takes yet. Share an insight, caveat, or question.
Borra et al. (2023) conducted a systematic review in Rheumatoid arthritis. Cardiac biomarkers (hsTropT, BNP, NT-proBNP) vs. Standard cardiovascular risk assessment was evaluated on Prediction of cardiovascular events and subclinical myocardial injury. Cardiac biomarkers, including high-sensitivity troponin T and B-type natriuretic peptide, act as effective predictors of subsequent cardiovascular events and subclinical myocardial injury in patients with rheumatoid arthritis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: